Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07944144
PHASE1/PHASE2

A Phase I/II Study to Learn About the Safety and Effects of a New Medicine Called IPN60350 Alone or in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Solid Tumors

Sponsor: Ipsen

View on ClinicalTrials.gov

Summary

The purpose of this study is to learn about the safety of a new medicine called IPN60350 and how the body responds to it. Researchers will also look for early signs of antitumor activity in adults with locally advanced or metastatic solid tumors. All participants in this study will receive IPN60350, either alone or in combination with other anticancer therapies. The study has two parts. * Phase Ia (dose escalation) will test IPN60350 at different dose levels to learn which doses are safe and can be given in future parts of the study. * Phase Ib (dose optimization and expansion) will test one or more selected dose levels in a larger number of participants. This will help researchers better understand the safety of IPN60350 and whether it shows early signs of antitumor activity in different tumor types. Each part will consist of the following periods: * A screening period (up to 28 days) to assess whether the participant can take part, requiring at least 1 visit to the study center. * A treatment period where IPN60350 is administered in repeating treatment cycles. The study includes health assessments, blood tests, tissue samples (biopsies), and imaging scans to help researchers better understand the safety of IPN60350 and its potential effects on tumors.

Official title: An Open-label Phase I/II, Dose Escalation, Dose Optimization, and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity, and Antitumor Activity of IPN60350 as Monotherapy or in Combination With Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumors

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

205

Start Date

2026-12-01

Completion Date

2030-09-30

Last Updated

2026-11-18

Healthy Volunteers

No

Interventions

BIOLOGICAL

IPN60350

IPN60350 will be administered at the assigned dose level.